IASO Completes $108 Million C Round for Novel Cell Therapies
publication date: Sep 16, 2021
IASO, a Nanjing biopharma, completed a $108 million Series C round to advance its novel cell therapy and biologic products for oncology and autoimmune diseases. The company will use the proceeds to develop its cell therapy portfolio and develop a pipeline of universal allogeneic cell therapies to treat solid tumors. The C round was led by CDH Baifu, and included CCB International, with participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital. Since its founding in 2017, IASO Bio has raised more than $178 million. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.